Other substances

RBD mRNA

Experimental viral mRNA-based vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

General information

Experimental viral mRNA-based vaccine delivered in lipid nanoparticles.

 

Supporting references

Link Tested on Impact factor Notes Publication date
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
BALB/c mice 20.51

Delivered in lipid nanoparticles. Elicited T follicular helper (Tfh), germinal center (GC) B, and plasma cell responses. Specific IgG and neutralizing antibodies were produced. Increased frequency of NF-α-producing CD45+CD4+ and IFN-γ- or IL-4-producing CD45+-CD8+ T cells, respectively.

 Aug/05/2020

AI-suggested references

Link Publication date
The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
Sep/09/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT05272605 Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Not yet recruiting Phase 1 Mar/15/2022 Dec/31/2022
  • Alternative id - UoM-SARS-CoV-2-01
  • Interventions - Biological: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Biological: SARS-CoV-2 beta variant RBD mRNA vaccine|Other: Normal Saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Vaccine and Immunisation Research Group, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Victorian Infectious Diseases Service (VIDS), Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 114
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Serious adverse events (SAEs), medically attended adverse events (MAAEs) and any adverse events (AEs) leading to study withdrawal at any time during the study.|SAEs post vaccination.|Solicited local and systemic reactogenicity AEs post vaccination.|Unsolicited AEs post vaccination.|Percentage of participants who achieve a boost response post vaccination.|MAAEs from Day 1 to 6 months after vaccination.|The number of participants that develop an antibody response at least 4 times higher than baseline antibody titers.|Number of participants that mount a T cell response for SARS-CoV-2 RBD-derived peptide antigens.|Number of participants that mount a T cell response that leads to type-1 cytokines (such as Interferon-gamma) versus type-2 cytokines (such as Interleukin 4, 5 and 13).|The ratio of T cell derived type 1 versus type 2 cytokines in participants that mount a T cell response.
Export (.csv)